Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-ass… Read more
Faron Pharmaceuticals Oy (FARN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.000x
Based on the latest financial reports, Faron Pharmaceuticals Oy (FARN) has a cash flow conversion efficiency ratio of 0.000x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-5.21K) by net assets (GBX-16.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Faron Pharmaceuticals Oy - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Faron Pharmaceuticals Oy's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Faron Pharmaceuticals Oy Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Faron Pharmaceuticals Oy ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SALINI IMPREGILO (IPJ1.SG)
STU:IPJ1
|
N/A |
|
SMTO3F
SA:SMTO3F
|
N/A |
|
Silver Bear Resources Plc
PINK:SVBRF
|
0.021x |
|
TANZANIA PORTLAND CEMENT CO. LTD
DSE:TPCC
|
N/A |
|
MJ Gleeson plc
LSE:GLE
|
0.070x |
|
Team India Guaranty Limited
NSE:TEAMGTY
|
-0.054x |
|
CARTIER SAADA
BC:CARTIER-SAADA
|
N/A |
|
W&T OFFSHORE (UWV.SG)
STU:UWV
|
-0.469x |
Annual Cash Flow Conversion Efficiency for Faron Pharmaceuticals Oy (2012–2024)
The table below shows the annual cash flow conversion efficiency of Faron Pharmaceuticals Oy from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX-9.76 Million | GBX-22.97 Million | 2.353x | +49.86% |
| 2023-12-31 | GBX-15.16 Million | GBX-23.81 Million | 1.570x | -21.63% |
| 2022-12-31 | GBX-11.48 Million | GBX-22.99 Million | 2.004x | +126.31% |
| 2021-12-31 | GBX2.92 Million | GBX-22.22 Million | -7.614x | -180.55% |
| 2020-12-31 | GBX-1.85 Million | GBX-17.48 Million | 9.453x | +232.08% |
| 2019-12-31 | GBX1.61 Million | GBX-11.52 Million | -7.157x | -12767.17% |
| 2018-12-31 | GBX369.00K | GBX-20.52K | -0.056x | +98.56% |
| 2017-12-31 | GBX4.74 Million | GBX-18.36 Million | -3.872x | -398.52% |
| 2016-12-31 | GBX10.88 Million | GBX-8.45 Million | -0.777x | -21.48% |
| 2015-12-31 | GBX11.18 Million | GBX-7.15 Million | -0.639x | -295.24% |
| 2014-12-31 | GBX-1.19 Million | GBX-389.00K | 0.327x | -59.54% |
| 2013-12-31 | GBX-949.00K | GBX-768.00K | 0.809x | -70.13% |
| 2012-12-31 | GBX-837.00K | GBX-2.27 Million | 2.710x | -- |